24 April 2019
SpeeDx Close Series A Fundraising With Support From U.S. Venture Firm
SpeeDx announced further series A funding received by new investor partners, Northpond Ventures, LP – a U.S.-based, formative stage venture...
16 April 2019
SpeeDx and Cepheid announce test partnership
SpeeDx Pty, Ltd. announced an agreement with Cepheid to manufacture their market-leading ResistancePlus® tests for use on the GeneXpert System....
15 April 2019
SpeeDx trusted assay partner for Cepheid FleXible for the GeneXpert program
ResistancePlus® MG will be the first test available through Cepheid's FleXible cartridge program. This partnership will increase access for clinicians...
26 March 2019
SpeeDx new US Headquarters
SpeeDx have successfully settled into new U.S. Headquarters at the Texas Health CoLab in Austin Texas. Chosen for its synergy...
19 March 2019
SpeeDx sign Middle East Distributor
New distribution partners, Al Zahrawi Medical Supplies LLC, will distribute SpeeDx ResistancePlus® and PlexPCR® tests across UAE, Saudi Arabia, Oman,...
15 February 2019
TGA clearance for ResistancePlus® GC
ResistancePlus® GC received clearance from the Australian Therapeutic Goods Administration (TGA) today. Launched in December with CE-IVD mark for sale...